S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Is This The End Of Your Retirement? (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Court battle over interstate travel targets Utah bus stops in Nevada, California
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Is This The End Of Your Retirement? (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Court battle over interstate travel targets Utah bus stops in Nevada, California
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Is This The End Of Your Retirement? (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Court battle over interstate travel targets Utah bus stops in Nevada, California
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Is This The End Of Your Retirement? (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Court battle over interstate travel targets Utah bus stops in Nevada, California
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Forecast, Price & News

$1.10
+0.01 (+0.92%)
(As of 06/2/2023 ET)
Compare
Today's Range
$1.07
$1.17
50-Day Range
$0.51
$1.43
52-Week Range
$0.24
$1.63
Volume
1.77 million shs
Average Volume
2.38 million shs
Market Capitalization
$204.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Akebia Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
81.8% Upside
$2.00 Price Target
Short Interest
Healthy
2.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
-0.13mentions of Akebia Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$261,587 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.28) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

287th out of 983 stocks

Pharmaceutical Preparations Industry

126th out of 486 stocks


AKBA stock logo

About Akebia Therapeutics (NASDAQ:AKBA) Stock

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKBA Stock News Headlines

Why 2023 Could Kick Off a "Cash Frenzy" in Stocks
But the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Analyst Ratings for Akebia Therapeutics
Why Shares of Akebia Therapeutics Were Up Tuesday
These 14 Biotech Stocks Hit New Highs, Did You Get In Early?
Akebia Therapeutics regains Nasdaq compliance
See More Headlines

AKBA Price History

AKBA Company Calendar

Last Earnings
3/09/2023
Today
6/03/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKBA
Employees
426
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.00
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+81.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-92,560,000.00
Pretax Margin
-20.79%

Debt

Sales & Book Value

Annual Sales
$271.03 million
Book Value
($0.08) per share

Miscellaneous

Free Float
179,086,000
Market Cap
$204.52 million
Optionable
Optionable
Beta
0.73

Key Executives

  • John P. ButlerJohn P. Butler
    President, Chief Executive Officer & Director
  • Michel DahanMichel Dahan
    Chief Operating Officer & Senior Vice President
  • David A. SpellmanDavid A. Spellman
    Treasurer, Chief Financial & Accounting Officer
  • Steven K. BurkeSteven K. Burke
    Chief Medical Officer & SVP-Research & Development
  • Michael Rabinowitz
    Vice President-Research













AKBA Stock - Frequently Asked Questions

Should I buy or sell Akebia Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AKBA shares.
View AKBA analyst ratings
or view top-rated stocks.

What is Akebia Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 1 year target prices for Akebia Therapeutics' stock. Their AKBA share price forecasts range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 81.8% from the stock's current price.
View analysts price targets for AKBA
or view top-rated stocks among Wall Street analysts.

How have AKBA shares performed in 2023?

Akebia Therapeutics' stock was trading at $0.5770 at the beginning of 2023. Since then, AKBA stock has increased by 90.6% and is now trading at $1.10.
View the best growth stocks for 2023 here
.

Are investors shorting Akebia Therapeutics?

Akebia Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 4,070,000 shares, a decrease of 9.6% from the April 30th total of 4,500,000 shares. Based on an average trading volume of 1,720,000 shares, the short-interest ratio is currently 2.4 days.
View Akebia Therapeutics' Short Interest
.

When is Akebia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AKBA earnings forecast
.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its earnings results on Thursday, March, 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. The biopharmaceutical company earned $55.18 million during the quarter, compared to analysts' expectations of $48.35 million. Akebia Therapeutics had a negative net margin of 20.79% and a negative trailing twelve-month return on equity of 235.17%.

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Alerce Investment Management L.P. (8.72%), BlackRock Inc. (1.45%), Renaissance Technologies LLC (1.26%), State Street Corp (0.37%), Connor Clark & Lunn Investment Management Ltd. (0.16%) and Victory Capital Management Inc. (0.14%). Insiders that own company stock include David A Spellman, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau.
View institutional ownership trends
.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $1.10.

How much money does Akebia Therapeutics make?

Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $204.52 million and generates $271.03 million in revenue each year. The biopharmaceutical company earns $-92,560,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

How many employees does Akebia Therapeutics have?

The company employs 426 workers across the globe.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for the company is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099.

This page (NASDAQ:AKBA) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -